Mounjaro – a popular treatment for diabetes is more effective for losing weight than Ozempic, as per a large study of real-word data by Truveta Research.
FDA recently approved a new named Mounjaro
On Monday, the healthcare data analytics firm said patients on Mounjaro saw a bigger decline in their body weight after three, six, and twelve months compared to those on Ozempic. According to Dr Nick Stucky – its Vice President:
This study can help to inform patient care and outcomes today, not months from now.
The news arrives only days after FDA approved Zepbound – a new version of Mounjaro for weight loss. Eli Lilly & Co (NYSE: LLY) attributed $1.44 billion of revenue from “new products” in its latest reported quarter led by Mounjaro.
$LLY is currently up about 90% versus its year-to-date low. Watch here: https://www.youtube.com/embed/XERGGMjQQ24?feature=oembed
How does Mounjaro compare with Wegovy?
Neither Eli Lilly nor Novo Nordisk A/S (NYSE: NVO) – the company behind Ozempic have so far commented on the analysis of about 18,000 adults that showed Mounjaro to be three times more effective than its peer in reducing weight by 15%.
Note that Lilly is comparing Mounjaro with a higher-dose variant of Ozempic known broadly as Wegovy as a treatment of obesity in a clinical trial results of which are expected in 2024.
Wegovy was a blockbuster drug for Novo Nordisk in its third financial quarter bringing in about $3.1 billion in revenue – more than double what Mounjaro generated for Eli Lilly in Q3.
Shares of Novo Nordisk have also gained close to 60% since early February.
The post Mounjaro is more effective for weight loss than Ozempic: study reveals appeared first on Invezz